Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia

被引：2

作者：

Qu, Wenqiang ^{[1
]}

Lu, Jialing ^{[2
]}

Ji, Yujie ^{[1
]}

He, Zhewei ^{[1
]}

Hou, Mengjia ^{[3
]}

Li, Dongyang ^{[3
]}

Yang, Yan ^{[3
]}

Liu, Dan ^{[3
]}

Chen, Suning ^{[1
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Shizi St 188, Suzhou 215006, Peoples R China

[2] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Shanghai, Peoples R China

[3] Soochow Hopes Hematonosis Hosp, Wudong Rd 1339, Suzhou 215100, Peoples R China

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2024年 / 94卷 / 04期

关键词：

Therapy-related acute myeloid leukemia; Palbociclib; CDK6; Venetoclax; Azacitidine; INHIBITOR; SECONDARY; NEOPLASMS; CANCER; CDK4;

D O I：

10.1007/s00280-024-04642-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundTherapy-related acute myeloid leukemia (t-AML) is considered high risk as it related to prior exposure to cytotoxic chemotherapy agents for solid tumors or hematologic malignancies. Compared with de novo AML, t-AML is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed.Case descriptionWe reported one patient with refractory/relapsed t-AML was successfully treated with Palbociclib combined with Venetoclax and Azacytidine (AZA). In this case, a 47-year-old patient with t-AML recurred during Venetoclax in combination with AZA therapy. However, the patient achieved morphological, immunophenotypic and molecular complete remission again after Palbociclib combined with Venetoclax and AZA.ConclusionsAlthough only one successful case is presented here, three-drug combination regimens should be considered as another treatment option for t-AML in the future.

引用

页码：635 / 639

页数：5

共 22 条

[1]

Almeida Antonio M, 2016, Leuk Res Rep, V6, P1, DOI 10.1016/j.lrr.2016.06.001

[2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[3] Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM) [J].

Cluzeau, Thomas ;

Sebert, Marie ;

Rahme, Ramy ;

Cuzzubbo, Stefania ;

Lehmann-Che, Jacqueline ;

Madelaine, Isabelle ;

Peterlin, Pierre ;

Beve, Blandine ;

Attalah, Habiba ;

Chermat, Fatiha ;

Miekoutima, Elsa ;

Rauzy, Odile Beyne ;

Recher, Christian ;

Stamatoullas, Aspasia ;

Willems, Lise ;

Raffoux, Emmanuel ;

Berthon, Celine ;

Quesnel, Bruno ;

Loschi, Michael ;

Carpentier, Antoine F. ;

Sallman, David A. ;

Komrokji, Rami ;

Walter-Petrich, Anouk ;

Chevret, Sylvie ;

Ades, Lionel ;

Fenaux, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (14) :1575-+

[4] Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial [J].

Dickson, Mark A. ;

Schwartz, Gary K. ;

Keohan, Mary Louise ;

D'Angelo, Sandra P. ;

Gounder, Mrinal M. ;

Chi, Ping ;

Antonescu, Cristina R. ;

Landa, Jonathan ;

Qin, Li-Xuan ;

Crago, Aimee M. ;

Singer, Samuel ;

Koff, Andrew ;

Tap, William D. .

JAMA ONCOLOGY, 2016, 2 (07) :937-940

[5] Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias [J].

Fianchi, Luana ;

Pagano, Livio ;

Piciocchi, Alfonso ;

Candoni, Anna ;

Gaidano, Gianluca ;

Breccia, Massimo ;

Criscuolo, Marianna ;

Specchia, Giorgina ;

Pogliani, Enrico Maria ;

Maurillo, Luca ;

Aloe-Spiriti, Maria Antonietta ;

Mecucci, Cristina ;

Niscola, Pasquale ;

Rossetti, Elena ;

Mansueto, Giovanna ;

Rondoni, Michela ;

Fozza, Claudio ;

Invernizzi, Rosangela ;

Spadea, Antonio ;

Fenu, Susanna ;

Buda, Gabriele ;

Gobbi, Marco ;

Fabiani, Emiliano ;

Sica, Simona ;

Hohaus, Stefan ;

Leone, Giuseppe ;

Voso, Maria Teresa .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) :E80-E85

[6] CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial [J].

Froehling, Stefan ;

Agrawal, Mridul ;

Jahn, Nikolaus ;

Fransecky, Lars R. ;

Baldus, Claudia D. ;

Waesch, Ralph ;

Luebbert, Michael ;

Walter, Gina ;

Jensen, Patrizia ;

Scholl, Claudia ;

Habdank, Marianne ;

Doehner, Konstanze ;

Doehner, Hartmut ;

Schlenk, Richard F. .

BLOOD, 2016, 128 (22)

[7] A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors [J].

Geoerger, Birgit ;

Bourdeaut, Franck ;

DuBois, Steven G. ;

Fischer, Matthias ;

Geller, James I. ;

Gottardo, Nicholas G. ;

Marabelle, Aurelien ;

Pearson, Andrew D. J. ;

Modak, Shakeel ;

Cash, Thomas ;

Robinson, Giles W. ;

Motta, Marlyane ;

Matano, Alessandro ;

Bhansali, Suraj G. ;

Dobson, Jason R. ;

Parasuraman, Sudha ;

Chi, Susan N. .

CLINICAL CANCER RESEARCH, 2017, 23 (10) :2433-2441

[8] Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials [J].

Grimwade, David ;

Hills, Robert K. ;

Moorman, Anthony V. ;

Walker, Helen ;

Chatters, Stephen ;

Goldstone, Anthony H. ;

Wheatley, Keith ;

Harrison, Christine J. ;

Burnett, Alan K. .

BLOOD, 2010, 116 (03) :354-365

[9] Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015-2020 [J].

Huntington, Scott F. ;

Ingham, Michael P. ;

Okonkwo, Linda ;

Singh, Ajaybir ;

Wang, Ruibin ;

Ammann, Eric M. .

LEUKEMIA & LYMPHOMA, 2022, 63 (05) :1180-1190

[10] Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias [J].

Kadia, Tapan M. ;

Konopleva, Marina Y. ;

Garcia-Manero, Guillermo ;

Benton, Christopher B. ;

Wierda, William G. ;

Bose, Prithviraj ;

Yilmaz, Musa E. ;

Jabbour, Elias J. ;

Kornblau, Steven M. ;

Bhalla, Kapil N. ;

Pemmaraju, Naveen ;

Jain, Nitin ;

Malla, Rashmi ;

Borthakur, Gautam ;

Cortes, Jorge E. ;

Ravandi, Farhad ;

Kantarjian, Hagop M. .

BLOOD, 2018, 132

← 1 2 3 →